Trial reportStem cell research & therapy2020
Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial.
Trial report in Stem cell research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02772289 (A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Mesenchymal stem cells therapy improves ovarian function in premature ovarian failure: a systematic review and meta-analysis based on preclinical studies.Frontiers in endocrinology · 2023Pooled it
- Topical application of a placental mesenchymal stem cell-embedded biomaterial hydrogel accelerates the repair of radiation-induced skin damage: a double-blind randomized phase II clinical trial.Journal of translational medicine · 2025Trial
- Investigating social appearance anxiety, fear of negative evaluation and body image and the use of personal care and cosmetic products during pregnancy.BMC pregnancy and childbirth · 2026Article
- Beyond wound closure: translational opportunities and barriers of mesenchymal stem cells and their extracellular vesicles in burn management.Frontiers in cell and developmental biology · 2026Review
- Systemic aging delay and anti-aging therapy using allogeneic stem cells.Korean journal of family medicine · 2025Article
- The application of tissue engineering strategies for uterine regeneration.Materials today. Bio · 2025Review
- The Differentiation and Regeneration Potential of ABCB5Journal of clinical medicine · 2025Review
- Mesenchymal stromal cell-laden hydrogels in tissue regeneration: insights from preclinical and clinical research.Frontiers in pharmacology · 2025Review
- HUC-MSCs combined with platelet lysate treat diabetic chronic cutaneous ulcers in Bama miniature pig.Regenerative therapy · 2024Article
- Role of umbilical cord mesenchymal stromal cells in skin rejuvenation.NPJ Regenerative medicine · 2024Review
- Advances in the Application of Black Phosphorus-Based Composite Biomedical Materials in the Field of Tissue Engineering.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mesenchymal Stem Cell-Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?Journal of inflammation research · 2024Review
- Stem cells in plastic surgery and aesthetic medicine.Postepy dermatologii i alergologii · 2023Review
- Decellularized Extracellular Matrix: The Role of This Complex Biomaterial in Regeneration.ACS omega · 2023Review
- Extracellular vesicle-based biovectors in chronic wound healing: Biogenesis and delivery approaches.Molecular therapy. Nucleic acids · 2023Review
- Effects of Bioactive Glasses (BGs) on Exosome Production and Secretion: A Critical Review.Materials (Basel, Switzerland) · 2023Review
- Urine-Derived Stem Cells for Epithelial Tissues Reconstruction and Wound Healing.Pharmaceutics · 2022Review
- The application of mesenchymal stromal cells (MSCs) and their derivative exosome in skin wound healing: a comprehensive review.Stem cell research & therapy · 2022Review
- Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPathological skin scars, caused by cesarean section, affected younger mothers esthetically and psychosocially and to some extent frustrated obstetricians and dermatologists. Umbilical cord mesenchymal stem cells (UC-MSCs), as a population of multipotent cells, are abundant in human tissues, providing several possibilities for their effects on skin scar tissues. Herein, we performed a randomized, double-blind, placebo-controlled, three-arm clinical trial, aiming to assess the efficacy and safety of UC-MSCs in the treatment of cesarean section skin scars among primiparous singleton pregnant women.
methodsNinety primiparous singleton pregnant women undergoing elective cesarean section were randomly allocated to receive placebo, low-dose (3 × 10
resultsAll the participants completed their trial of the primary outcome according to the protocol. The mean score of estimated total VSS was 5.52 in all participants at the sixth-month follow-up, with 6.43 in the placebo group, 5.18 in the low-dose group, and 4.71 in the high-dose group, respectively. No significant difference was found between-group in the mean scores for VSS at the sixth month. Additional prespecified secondary outcomes were not found with significant differences among groups either. No obvious side effects or adverse effects were reported in any of the three arms.
conclusionThis randomized clinical trial showed that UC-MSCs did not demonstrate the effects of improvement of cesarean section skin scars.
trial registrationClinicalTrials.gov identifier, NCT02772289. Registered on 13 May 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.